---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "Xu+xGRVxtW35ap2yAKYKMC8DvICduuJEh+fwN++kXtnzbi82iju5THpMlQXe+Fe9S+4+tbqwk3Oagv6xvVZ5mrbD0on0ep6doj8856sDAw6FgJw7exYVD4S9IkyhK5zB0M8u5jhvucATFQku7OnzLn9q7gRvh6NVK3lqqLMuPZf3GhV5V0bfP9PyY5caud0PH6c43GA7hhsvQVuUL+7+M1HK4W685gn7I/t8vSGGHG1eeaCagk73f/JIgBNU42p/s3klr3gcPCdcbJxBT9YOz+ArGruoWgr2JpAiqV+JP/gkuDkIGmwbGZixf69Opqw2hLYAHh8kjgs3+12PdzQhzE43YkvO2uReJ7L0xO4/caY=;Vq+HvBWtyA72U2RFrRcMtw=="
---

